Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 1/20 | 0.33 |
| ▸ | RGS8 | P57771 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351576 | 0.82 | RGS4 (0.32) | RGS4RGS8PDE4AADORA2AADORA2B | |
| SCHEMBL2241714 | 0.81 | MGLL (0.31) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL17035933 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL23524453 | 0.72 | HSD17B10 (0.38) | — | |
| SCHEMBL1100298 | 0.71 | ALDH1A1 (0.40) | RGS4RGS8ADORA2B | |
| SCHEMBL471918 | 0.71 | GAA (0.41) | ADORA2B | |
| SCHEMBL18619592 | 0.71 | GAA (0.41) | ADORA2B | |
| SCHEMBL10384751 | 0.70 | MGLL (0.37) | PDE4AADORA2AADORA2BPDE4BPDE4C | |
| SCHEMBL18040340 | 0.68 | — | — | |
| SCHEMBL19698629 | 0.67 | GAA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509609-B2 | Curable resin composition, resin cured film, partition wall and optical element | AGC Inc. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20240392157-A1 | CURABLE RESIN COMPOSITION, RESIN CURED FILM, PARTITION WALL AND OPTICAL ELEMENT | AGC Inc. (JP) | 2024-11-28 | — | — | US | disclosed |
| CN-118660924-A | Curable resin composition, resin cured film, partition wall, and optical element | ＡＧＣ株式会社 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023149406-A1 | CURABLE RESIN COMPOSITION, RESIN CURED FILM, PARTITION WALL AND OPTICAL ELEMENT | ＡＧＣ株式会社 | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509609-B2 | Curable resin composition, resin cured film, partition wall and optical element | EED, ASH2L, ELL | RGS4 3993/4885RGS8 4549/4885PDE4A 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.